KLK3 and metastatic prostate carcinoma: In a more recent study known as the TRANSFORMER trial, these authors conducted a randomized phase II study comparing BAT versus standard treatment with enzalutamide—a potent agent that interferes with androgen action—in asymptomatic men with castrate-resistant metastatic prostate cancer.24 They found that BAT demonstrated similar time to progression and prostate-specific antigen response.